- Home
- DARE vs DRRX Comparison
DARE vs DRRX Comparison
Compare DARE & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- DRRX
- Stock Information
- Founded
- DARE N/A
- DRRX 1998
- Country
- DARE United States
- DRRX United States
- Employees
- DARE N/A
- DRRX N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- DARE Health Care
- DRRX Health Care
- Exchange
- DARE Nasdaq
- DRRX Nasdaq
- Market Cap
- DARE 27.9M
- DRRX 26.3M
- IPO Year
- DARE N/A
- DRRX 2000
- Fundamental
- Price
- DARE $3.17
- DRRX $0.80
- Analyst Decision
- DARE Strong Buy
- DRRX Buy
- Analyst Count
- DARE 4
- DRRX 2
- Target Price
- DARE $20.33
- DRRX $5.00
- AVG Volume (30 Days)
- DARE 25.7K
- DRRX 54.3K
- Earning Date
- DARE 03-27-2025
- DRRX 03-26-2025
- Dividend Yield
- DARE N/A
- DRRX N/A
- EPS Growth
- DARE N/A
- DRRX N/A
- EPS
- DARE N/A
- DRRX N/A
- Revenue
- DARE $1,881,316.00
- DRRX $8,594,000.00
- Revenue This Year
- DARE N/A
- DRRX $54.32
- Revenue Next Year
- DARE $136.52
- DRRX N/A
- P/E Ratio
- DARE N/A
- DRRX N/A
- Revenue Growth
- DARE 88.13
- DRRX N/A
- 52 Week Low
- DARE $2.67
- DRRX $0.70
- 52 Week High
- DARE $7.56
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- DARE 50.64
- DRRX 49.63
- Support Level
- DARE $2.95
- DRRX $0.73
- Resistance Level
- DARE $3.31
- DRRX $0.83
- Average True Range (ATR)
- DARE 0.15
- DRRX 0.05
- MACD
- DARE 0.01
- DRRX 0.01
- Stochastic Oscillator
- DARE 61.11
- DRRX 63.57
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .